Teewinot Life Sciences is an international biopharmaceutical company based in Tampa, Florida, focused on discovery, development and commercialization of cannabinoid-based therapeutics and on biocatalytic production of cannabinoids. The company emphasizes advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture. Teewinot operates proprietary production systems used to manufacture industrial quantities of pharmaceutically pure cannabinoids, including CBGA, CBG, THCA, THC, CBD and numerous others. Financially, the company closed a $12.3M Series B funding round. Proceeds from the round are intended to enhance and accelerate research and development activities, expand business development opportunities, and add to the company's existing patent portfolio. The company previously raised a $7M Series A in December 2015, also led by its current Series B lead investor. CBC Biotechnologies, based in Tampa, Florida, leverages synthetic biology to produce pharmaceutical-grade cannabinoids. The company focuses on production of cannabinoids and on discovery, development and commercialization of cannabinoid-based therapeutics for significant unmet medical needs worldwide. It has pioneered proprietary methods that enable rapid production of biocatalyzed cannabinoids that are purer and have a reduced environmental impact. Leadership includes Jeffrey Korentur (President and CEO), Dr. Richard Peet (Executive Vice President), and Christopher Brink (Co-Founder and Director). CBC completed a $7M Series A to fund continued development of its programs.

Total raised

$19M

Funding rounds

2

Latest round

Series B

Latest activity

May 2017